Naltrexone-Risperidone Composition for Cannabis Relapse Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cannabis addiction are ineffective in preventing relapse and managing adverse symptoms, and there is a need for a drug that can effectively prevent relapse into cannabis use and treat associated psychiatric symptoms.
Innovation Solution
A pharmaceutical composition comprising naltrexone and risperidone, administered at specific weight ratios and dosages, is used to prevent relapse into cannabis use and treat adverse symptoms such as anxiety, depression, and hallucinations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used for detoxification treatment of cannabis addiction, then the addiction symptoms are treated, but the relapse prevention efficacy is not significant
Solution Approach 1:
The patent combines naltrexone and risperidone into a single pharmaceutical composition for the treatment of cannabis addiction. Naltrexone addresses the opioid receptor pathway while risperidone targets dopamine and serotonin receptors, creating a multi-target treatment approach that simultaneously addresses detoxification and relapse prevention, thereby resolving the contradiction between treating addiction symptoms and preventing relapse
Solution Approach 2:
The invention uses a composite pharmaceutical formulation containing two distinct active ingredients (naltrexone and risperidone) with different mechanisms of action. This composite approach allows the medication to address multiple aspects of cannabis addiction pathology simultaneously, improving both detoxification effectiveness and relapse prevention compared to single-agent therapies
2Power
If cannabis is used for clinical anesthesia, then anesthetic effect is achieved, but addiction and side effects occur
Solution Approach 1:
The patent converts the harmful addictive effects of cannabis into a beneficial treatment approach by using naltrexone and risperidone to block the reward pathways and receptor sites that cannabis activates. The medication transforms the underlying mechanism of cannabis addiction into a therapeutic tool for preventing relapse and managing withdrawal symptoms
Solution Approach 2:
The pharmaceutical composition acts as an intermediary substance that blocks the interaction between cannabis and its target receptors in the brain. Naltrexone and risperidone serve as mediators that prevent cannabis from binding to opioid and dopamine receptors, thereby eliminating the addictive effects while managing withdrawal symptoms without requiring direct cannabis administration
3Reliability
If naltrexone and risperidone are administered separately, then each drug acts on its target, but synergistic effect is not achieved
Solution Approach 1:
The patent merges naltrexone and risperidone into a single combined pharmaceutical composition, allowing both medications to be administered together as one treatment regimen. This combination approach achieves synergistic effects by simultaneously targeting multiple neurotransmitter systems involved in cannabis addiction, while simplifying the treatment protocol compared to separate administrations
Solution Approach 2:
The combined pharmaceutical composition serves multiple functions simultaneously: it provides detoxification support, prevents relapse, and manages psychiatric symptoms associated with cannabis withdrawal. The dual-ingredient formulation acts as a universal treatment that addresses various aspects of cannabis addiction through a single medication regimen
Data Source
AI summary
A pharmaceutical composition for preventing relapse into cannabis use, and related therapeutic uses are disclosed. The pharmaceutical composition includes an active pharmaceutical ingredient of naltrexone and risperidone, which may be used for treating a patient suffering from a cannabis addiction disorder or any condition or symptom associated with the cannabis addiction disorder, alleviating adverse symptoms caused by cannabis addiction, and preventing relapse into cannabis use in a patient recovering from the treatment of cannabis abuse addiction.